Bruce E Gerlitz

US Patent:

6630138, Oct 7, 2003

Filed:

Jul 22, 2002

Appl. No.:

10/182263

Inventors:

Bruce Edward Gerlitz - Indianapolis IN
Brian William Grinnell - Indianapolis IN
Bryan Edward Jones - Carmel IN

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

C12N 964

US Classification:

424 9464, 4353201, 43525233, 435226, 536 232

Abstract:

Novel human protein C derivatives are described. These derivatives have increased anti-coagulation activity, resistance to serpin inactivation, and increased sensitivity to thrombin activation compared to wild-type protein C and retain the biological activity of the wild-type human protein C. These derivatives will require either less frequent administration and/or smaller dosage than wild-type human protein C in the treatment of acute coronary syndromes, vascular occlusive disorders, hypercoagulable states, thrombotic disorders and disease states predisposing to thrombosis.

US Patent:

6841371, Jan 11, 2005

Filed:

Jan 19, 2001

Appl. No.:

10/168407

Inventors:

Bruce Edward Gerlitz - Indianapolis IN, US
Bryan Edward Jones - Carmel IN, US

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

C12N 964
A01N 6100
A01N 2500
A61K 3828
A61K 3500
A61K 3514

US Classification:

435226, 514 1, 514 4, 514802, 514822, 424 9464, 530381, 530830

Abstract:

Novel human protein C derivatives are described. These derivatives have increased anti-coagulation activity and resistance to inactivation by serpins, compared to wild-type protein C and retain the biological activity of the wild-type human protein D. These derivatives will require either less frequent administration and/or smaller dosage than wild-type human protein C in the treatment of acute coronary syndromes, vascular occlusive disorders, hyper coagulable states, thrombotic disorders and disease states predisposing to thrombosis.

US Patent:

6998122, Feb 14, 2006

Filed:

Apr 13, 2000

Appl. No.:

09/719911

Inventors:

Bruce Edward Gerlitz - Indianapolis IN, US
Bryan Edward Jones - Carmel IN, US
David Thompson Berg - Beech Grove IN, US

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 38/48
C12N 9/64
C12N 15/00
C12N 5/00
C07H 21/04

US Classification:

424 9464, 435226, 4353201, 435325, 536 232

Abstract:

Novel protein C derivatives are described. These polypeptides retain the biological activity of the wild-type human protein C with substantially longer half-lives in human blood. These polypeptides will require either less frequent administration and/or smaller dosage than wild-type human protein C in the treatment of vascular occlusive disorders, hypercoagulable states, thrombotic disorders and disease states predisposing to thrombosis.

US Patent:

20060204489, Sep 14, 2006

Filed:

Apr 3, 2006

Appl. No.:

11/397046

Inventors:

Bruce Gerlitz - Indianapolis IN, US
Brian Grinnell - Indianapolis IN, US
Lihua Huang - Carmel IN, US
Bryan Jones - Carmel IN, US

International Classification:

A61K 38/48
C12N 9/64

US Classification:

424094630, 530325000, 435226000

Abstract:

Novel human protein C derivatives are described. These derivatives have increased anti-coagulation activity compared to wild-type protein C and retain the biological activity of the wild-type human protein C. These derivatives will require either less frequent administration and/or smaller dosage than wild-type human protein C in the treatment of acute coronary syndromes, vascular occlusive disorders, hypercoagulable states, thrombotic disorders and disease states predisposing to thrombosis.

US Patent:

52701786, Dec 14, 1993

Filed:

Feb 23, 1990

Appl. No.:

7/484133

Inventors:

Bruce E. Gerlitz - Indianapolis IN
Brian W. Grinnell - Indianapolis IN

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

C12P 2102

US Classification:

435 691

Abstract:

A method for the recombinant production of zymogen forms of human protein C is described. These zymogen forms differ from native zymogen protein C in their increased sensitivity to activation by thrombin and thrombin/thrombomodulin. DNA compounds, vectors, and transformants useful in the method are also disclosed.

US Patent:

54609534, Oct 24, 1995

Filed:

Sep 9, 1993

Appl. No.:

8/093217

Inventors:

Bruce E. Gerlitz - Indianapolis IN
Brian W. Grinnell - Indianapolis IN

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

C12N 964
C12N 1557
C12N 1570
C12N 1579

US Classification:

435226

Abstract:

A method for the recombinant production of forms of human protein C with higher activity is described. These forms differ from native protein C in their increased amidolytic and functional activities and novel carbohydrate structures. DNA compounds, vectors, and transformants useful in the method are also disclosed.

US Patent:

54533732, Sep 26, 1995

Filed:

Jul 9, 1993

Appl. No.:

8/089215

Inventors:

Bruce E. Gerlitz - Indianapolis IN
Brian W. Grinnell - Indianapolis IN

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

C12N 500
C12N 1500
C12P 2106
C07H 1900

US Classification:

4352402

Abstract:

Human protein C derivatives with high activity and reduced dependence on thrombin activation are described. These derivatives differ from the native forms of human protein C in their increased activation rates, functional activities and carbohydrate structures. DNA compounds, transfer vectors, expression vectors and transformants useful in producing these derivatives are also described.